Changsheng Biotechnology, the drugmaker at the centre of China’s latest safety scandal, slumped for a seventh straight session on Tuesday as public outrage over a revelation that the company sold fake vaccines intensified and authorities launched an investigation.
Shares in the Shenzhen-listed group fell by the 10 per cent daily maximum allowed within minutes of opening trade, extending their decline since July 13 to 52 per cent.
The wider Shenzhen CSI 300 Health Care Index, which tracks the performance of 22 pharmaceutical stocks, was also knocked lower, falling 1 per cent following Monday’s 4 per cent drop.
您已阅读52%（615字），剩余48%（557字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。